Hepatitis B remains a major public health problem worldwide and hepatitis B virus (HBV) is the chief inductive factor of acute and chronic hepatitis.
Anti-hepatitis B Virus Activities of Astragaloside IV Isolated from Radix Astragali
C-NMR (pyridine-d 5 ) data that were in agreement with those from the literature.
8)
Cell Culture The human HBV-infected cell line HepG 2 2.2.15 9) was from the Institute of Medical Technology, Peking Union Medical College and Chinese Academy of Medical Sciences. The cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/l L-glutamine (all from Invitrogen, U.S.A.) at 37°C in an atmosphere of 5% CO 2 and a 100% humidity. Test reagents were dissolved in DMSO and lamivudine (3TC) was used as the positive control. Cells were seeded in 24-well tissue culture plates at approximately 1ϫ10 6 /ml, and grown in medium containing 0.2% DMSO. At 48 h after confluence, test reagents at indicated concentrations were added into cultures, and were changed with fresh media every 2 d. Nine days after treatment, cell culture supernatants and HepG 2 2.2.15 cells were collected separately and stored at Ϫ70°C until analysis. The cell culture supernatants were used to measure the concentrations of HBsAg and HBeAg secreted from the cells.
Toxicity Measurements Cells were grown to confluence in 96-well tissue culture plates at 2ϫ10 5 cells/well and treated with astragaloside IV at one of five concentrations from 50 to 800 mg/ml. Four days after the final addition of compound, culture media were removed and astragaloside IV was added for an additional 4 d. MTT solution (10 ml/100 ml medium) was then added to all the wells, and incubation continued at 37°C for 4 h, followed by addition of acid-isopropanol (100 ml of 0.04 N HCl in isopropanol) to dissolve the dark blue crystals developed from MTT. Then, the plates were read directly by microplate reader at a wavelength of 490 nm.
10)
Assays for HBsAg and HBeAg in the Cell Culture After incubation with different extracts or isolated compounds at various concentrations at 37°C for 9 d, the culture media were collected and measured for their HBsAg or HBeAg concentrations with an enzyme-linked immunosorbent assay (ELISA) kit (Keuh HH Hua Inc., China) following the manufacturer's protocol. Each measurement was performed in triplicate. The inhibition rates (%) of the test reagents on the HBsAg or HBeAg contents were calculated by the following formula:
In Vivo Assays for Anti-DHBV Activity of Astragaloside IV in Ducklings One-day-old ducklings were purchased from Kunshan Wendefu Duck Farm of Jiangsu Province, and were maintained under normal daylight and fed with a standard commercial diet and water ad libitum. They were intravenously infected with a 5.7ϫ10 6 viral DNA equivalent (VGE, 1VGEϭ3.3ϫ10 6 pg) of duck hepatitis B virus (DHBV) by a previously reported method.
11) Seven days later, they were divided into three experimental groups, and were fed with astragaloside IV dissolved in physiological saline mixed in a liquid diet at one of the three concentrations, 120, 40, or 10 mg/kg for 10 d. The negative control group received the same liquid diet without any drug, and the positive control group received 200 mg/kg 3TC in the liquid diet without astragaloside IV. At days 10 and 13 from the beginning of drug treatment, blood samples were collected from the DHBV-infected ducklings and sera obtained. The DHBsAg (S antigen of DHBV) in the serum samples was assayed by dot-blotting based on a reported method using antiDHBsAg antibody. 12) All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health.
Southern-Blot Analysis of DHBV DNA in Duck Liver One gram of duck liver tissues was ground in 4 ml of a buffer (10 mM Tris-HCl, pH 7.6, 0.15 M NaCl, 1.27 mM EDTA, 20 mg/ml SDS, 5 mg/ml salmon sperm DNA, and 0.5 mg/ml proteinase K) at 50°C for 3 h, and centrifuged at 13000ϫg for 10 min. The supernatant was extracted with phenol/chloroform and DNA precipitated with two volumes of ethanol and 1/10 volume of acetic acid. The DNA was then dissolved in 800 ml of TE buffer (10 mM Tris-HCl, pH 7.5, containing 2 mM EDTA and 100 mg/ml RNase A) and separated on a 1% agarose gel. The gel with fractionated DNA samples was then subjected to Southern blotting and hybridized with a DHBV DNA probe as previously described.
13)

RESULTS
In Vitro Anti-HBV Activity of Astragaloside IV in HepG 2 2.2.15 Cells The cytotoxicity of astragaloside IV was measured in cultured HepG 2 2.2.15 cells. It showed no inhibitory effect on cell proliferation at a concentration up to 200 mg/ml, as analyzed by MTT assay. The 50% cytotoxic concentration was determined to be 388 mg/ml. These results were further used to determine the dose range of astragaloside IV for the following experiments.
Astragaloside IV effectively suppressed secretion of HBV antigens from virus-infected HepG 2 2.2.15 cells, achieving 31.8%, 23.6%, and 19.7% inhibition to the secretion of HBsAg, and 23.3%, 22.9%, and 19.2% inhibition to that of HBeAg, respectively, at 200, 100, and 40 mg/ml after 9 d of treatment (Fig. 2) . In the same experiment, 3TC at 100 mg/ml also suppressed the secretion of both HBsAg and HBeAg, at the rates of 20.1% and 19.7%, respectively (Fig. 2) . Apparently the inhibitory activity of astragaloside IV on the secretion of HBV antigens is more potent than that of 3TC.
In Vivo Anti-HBV Activity of Astragaloside IV in Ducks During the experiments, all ducklings were raised under the same standard conditions. The drug treatments exhibited no significant toxicity to the animals since all ducklings in the experimental and control groups grew equally well, and there were no significant weight losses or gains or abnormal behaviors observed in the animals while on the treatment scheme.
As shown in Fig. 3 , astragaloside IV reduced DHBV levels in the serum of infected ducks, achieving 64.0% inhibition at 120 mg/kg, 49.6% inhibition at 40 mg/kg, and 41.7% inhibition at 10 mg/kg after 10 d of treatment. Interestingly, at day 13 (3 d after the end of treatment), the inhibition rates of astragaloside IV on serum DHBVs were 69.1%, 48.2%, 49.4%, respectively, at the three concentrations tested. At the same time, the inhibition rate of 3TC at 200 mg/kg was 68.5% on day 10 and 52.6% on day 13 (Fig. 3) .
Further to investigate the in vivo anti-HBV effect of astragaloside IV in ducks, DHBV DNA levels in the liver of infected ducks obtained on day 3 after the end of treatment were examined by Southern blotting. Densitometric analysis of the autoradiographic signals showed inhibition rates of 18.3%, 16.5%, and 0% by astragaloside IV at 120, 40, and 10 mg/kg, respectively, and 40.1% inhibition by 3TC at 200 mg/kg.
DISCUSSION
The anti-HBV activity of astragaloside IV was confirmed from our in vitro experiments by its suppression of HBV secretion from HepG 2 2.2.15 cells. More importantly, this activity was confirmed by its ability to reduce serum DHBV and its DNA levels in the DHBV-infected ducks.
To date, there has been only one report on the anti-HBV activity of astragaloside IV 7) and another isolated report on the anti-HBV activity of total saponins of Radix Astragali.
14)
Previously, we isolated anti-HBV compounds from total saponins and examined the inhibitory effect of astragaloside IV on HBV in vitro and in vivo. Here, we show that astragaloside IV exhibited potent inhibitory activity against antigen secretion in HBV-transfected HepG 2 2.2.15 cells, which is consistent with the previous report. 4) In the present study, astragaloside IV inhibited 23.6% of the HBsAg expression and 22.9% HBeAg secretion from cultured HepG 2 2.2.15 cells at a concentration of 200 mg/ml. Because human HepG 2 2.2.15 cells carry multiple copies of HBV DNA stably integrated into the host cell genome, 9) they well resemble infected human liver cells, therefore offering a great cell system. Indeed, they have been widely used for the evaluation of anti-HBV drugs. It is worth noting that the potency of astragaloside IV was much higher than the known anti-HBV drug 3TC. 3TC is known to reduce HBsAg by a mechanism where it is phosphorylated inside HepG 2 2.2.15 cells and subsequently incorporated into nascent viral DNA by HBV polymerase during replication.
Since a human system is not practical, we used the duck DHBV model that has been widely used for studies of in vivo activity and toxicity of anti-HBV agents, as shown in many similar studies.
15) The present study demonstrates, for the first time, that astragaloside IV has potent anti-HBV activity in vivo in DHBV-infected ducks. Astragaloside IV reduced levels of DHBsAg in the duck sera. In addition, astragaloside IV showed 18.3% inhibition of DHBV DNA levels in the liver at 120 mg/kg, and 3TC showed 40.1% inhibition at 200 mg/kg. Inhibition of DHBV-DNA by astragaloside IV was not as high as that by 3TC. This is most likely due to its low solubility in water, leading to a relatively lower bioavailability of the drug via oral administration. Interestingly, the anti-HBV effects of astragaloside IV on DHBVs lasted for Astragaloside IV reduced the levels of DHBV DNA in infected ducks. After astragaloside IV treatment (120, 40, or 10 mg/kg), duck livers were removed and DNA was extracted at 3 d after cessation of treatment. DNA levels were analyzed by Southern hybridization. 3TC (200 mg/kg) was used as control. The experiments were performed three times, and a representative set of data are presented.
Ն3 d, indicating that astragaloside IV is a relatively longlasting drug in ducks as compared with the effects of 3TC. This long duration of astragaloside IV's activity may offer better clinical benefits and therefore supports the significance of developing astragaloside IV as an anti-HBV drug.
In conclusion, our data demonstrate that astragaloside IV has potent anti-HBV activity, and deserves to be further evaluated for the treatment of human HBV infection. Currently, astragaloside IV is under early development as an anti-HBV drug candidate.
